Steven Degalan, MD
Interventional Cardiology · Fremont, CANPI 1508849860
Payments from drug & device makers
Across 668 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$2K
- Abbott$1K
- Johnson & Johnson$995
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$981
- plus $8K from 33 others
What the payments were for
- Consulting fees$1501%
- Travel & lodging$6364%
- Food & beverage$14,84692%
- Education$5093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 34 | $2,007 |
| Actelion Pharmaceuticals US, Inc. | 74 | $1,704 |
| Boehringer Ingelheim | 60 | $1,539 |
| Abbott | 45 | $1,270 |
| Johnson & Johnson | 60 | $995 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $981 |
| Boston Scientific | 32 | $978 |
| Bayer | 39 | $879 |
| E.r. Squibb & Sons, L.L.C. | 43 | $864 |
| Pfizer | 43 | $768 |
| Novo Nordisk | 48 | $727 |
| Merck | 28 | $672 |
| Avanir Pharmaceuticals, Inc. | 21 | $514 |
| AstraZeneca | 22 | $358 |
| Novartis | 15 | $319 |
| Amgen | 15 | $318 |
| Sanofi-aventis U.S. LLC | 9 | $169 |
| Comsort, Inc | 1 | $150 |
| Esperion Therapeutics, Inc. | 9 | $149 |
| Regeneron Healthcare Solutions, Inc. | 7 | $119 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $83 |
| Heartflow, Inc. | 3 | $80 |
| Gilead | 4 | $75 |
| Lexicon Pharmaceuticals, Inc. | 2 | $55 |
| Lilly USA, LLC | 2 | $51 |
| Philips North America LLC | 1 | $42 |
| SNAP Diagnostics LLC | 2 | $31 |
| Aegerion Pharmaceuticals, Inc. | 2 | $30 |
| Baxter Healthcare | 1 | $29 |
| Octapharma USA, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Medicomp Inc | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALLANT$328
- BioMonitor$238
- PNEUMOVAX 23$150
- JOT DX$144
- ASSURITY$137
- Rivacor$114
- Solia$114
- Edora$114
- Acticor$114
- LifeVest$111
- Watchman$108
- WATCHMAN Access System$101
How this compares
$16,141 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 247 | $276,084 |
| AdempasRiociguat | 12 | $196,250 |
| OpsumitMacitentan | 12 | $141,753 |
| JardianceEmpagliflozin | 95 | $79,477 |
| XareltoRivaroxaban | 60 | $69,973 |
| EntrestoSacubitril/Valsartan | 81 | $69,935 |
| MultaqDronedarone Hcl | 44 | $54,501 |
| OzempicSemaglutide | 47 | $39,544 |
| FarxigaDapagliflozin Propanediol | 25 | $28,191 |
| ProliaDenosumab | 16 | $26,499 |
| JanuviaSitagliptin Phosphate | 17 | $15,351 |
| Repatha SyringeEvolocumab | 21 | $12,328 |
| RybelsusSemaglutide | 14 | $11,739 |
| AliskirenAliskiren Hemifumarate | 35 | $11,319 |
| Propafenone Hcl ErPropafenone Hcl | 14 | $4,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $768 | $276,084247 claims |
| BayerAdempas | $879 | $196,25012 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,704 | $141,75312 claims |
| Boehringer IngelheimJardiance | $1,539 | $79,47795 claims |
| Johnson & JohnsonXarelto | $995 | $69,97360 claims |
| NovartisEntresto | $319 | $69,93581 claims |
| Sanofi-aventis U.S. LLCMultaq | $169 | $54,50144 claims |
| Novo NordiskOzempic, Rybelsus | $727 | $51,28461 claims |
| AstraZenecaFarxiga | $358 | $28,19125 claims |
| AmgenProlia | $318 | $26,49916 claims |
| MerckJanuvia | $672 | $15,35117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Fremont
- Rajendra MakkarWest Hollywood$16.6M
- Fahed BitarCovina$9.9M
- Rahul SharmaStanford$6.6M
- Matthew Pricela Jolla$5.8M
- David LeeStanford$5.7M
- Saibal KarThousand Oaks$5.4M
- Mehrdad ArianiNorthridge$5M
- Frederick St GoarMountain View$4.2M
- Sammy ElmariahSan Francisco$4.2M
- William FearonStanford$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.